接受体外膜氧合支持的COVID-19患者炎症标志物升高时颅内出血增加
本研究在两个学术医疗中心回顾性评估了因ARDS接受VV-ECMO支持的COVID-19患者颅内出血的发生率与病因。研究期间共33例患者需要ECMO支持,16例(48.5%)存活出院,13例(39.4%)死亡,4例(12.1%)仍在治疗中。11例发生ICH(33.3%),所有ICH事件均发生在接受静脉抗凝治疗的患者中。ICH组C反应蛋白(P = 0.04)、降钙素原(P = 0.02)、IL-6(P = 0.05)更高,ECMO前后血pH更低(P < 0.01),住院期间活化部分凝血活酶时间更高(P < 0.0001)。COVID-19患者无ICH生存率低于其他病毒所致ARDS的ECMO患者(49% vs 79%,P = 0.02)。
要点
- 33例COVID-19 ARDS接受VV-ECMO的患者中11例(33.3%)发生颅内出血,所有ICH事件均发生在接受静脉抗凝治疗的患者中。
- ICH组C反应蛋白(P = 0.04)、降钙素原(P = 0.02)、IL-6(P = 0.05)更高,ECMO前后血pH更低(P < 0.01),住院期间活化部分凝血活酶时间更高(P < 0.0001)。
- COVID-19患者无ICH生存率为49%,其他病毒所致ARDS的ECMO患者为79%(P = 0.02)。
- 研究期间33例患者中16例(48.5%)存活出院,13例(39.4%)死亡,4例(12.1%)仍在治疗中。
适用人群与场景
- 两个学术医疗中心中因COVID-19相关ARDS需要静脉-静脉体外膜氧合(VV-ECMO)支持的患者。
研究设计与关键结果
- 回顾性评估两个学术医疗中心因COVID-19 ARDS接受VV-ECMO支持的患者,研究期间33例需要ECMO支持。
- 33例中16例(48.5%)存活出院,13例(39.4%)死亡,4例(12.1%)仍在治疗中。
- 11例发生颅内出血(33.3%),所有ICH事件均发生在接受静脉抗凝治疗的患者中。
- ICH组C反应蛋白更高(P = 0.04)、降钙素原更高(P = 0.02)、IL-6更高(P = 0.05)。
- ICH组ECMO前后血pH更低(P < 0.01),住院期间活化部分凝血活酶时间更高(P < 0.0001)。
- COVID-19患者无ICH生存率低于其他病毒所致ARDS的ECMO患者(49% vs 79%,P = 0.02)。
证据类型、等级与局限
- 回顾性研究,两个学术医疗中心,样本量33例。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,COVID-19患者可通过ECMO成功过渡至康复,但与其他病毒性呼吸道感染相比可能发生更高的ICH发生率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
COVID-19-related coagulopathy is a known complication of SARS-CoV-2 infection and can lead to intracranial hemorrhage (ICH), one of the most feared complications of extracorporeal membrane oxygenation (ECMO). We sought to evaluate the incidence and etiology of ICH in patients with COVID-19 requiring ECMO. Patients at two academic medical centers with COVID-19 who required venovenous-ECMO support for acute respiratory distress syndrome (ARDS) were evaluated retrospectively. During the study period, 33 patients required ECMO support; 16 (48.5%) were discharged alive, 13 died (39.4%), and 4 (12.1%) had ongoing care. Eleven patients had ICH (33.3%). All ICH events occurred in patients who received intravenous anticoagulation. The ICH group had higher C-reactive protein (P = 0.04), procalcitonin levels (P = 0.02), and IL-6 levels (P = 0.05), lower blood pH before and after ECMO (P < 0.01), and higher activated partial thromboplastin times throughout the hospital stay (P < 0.0001). ICH-free survival was lower in COVID-19 patients than in patients on ECMO for ARDS caused by other viruses (49% vs. 79%, P = 0.02). In conclusion, patients with COVID-19 can be successfully bridged to recovery using ECMO but may suffer higher rates of ICH compared to those with other viral respiratory infections.
参考来源
- Bermea RS, Raz Y, Sertic F, et al. Increased Intracranial Hemorrhage Amid Elevated Inflammatory Markers in Those With COVID-19 Supported With Extracorporeal Membrane Oxygenation. Shock. 2021. PMID: 33587724. doi:10.1097/SHK.0000000000001730
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。